Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy

Abstract

The objective of this study was to provide population based estimates on the cost of HIV service provision in England and the use of dual or triple antiretroviral combination therapy. Contemporary cost estimates of treating HIV infected individuals by clinical stage of HIV infection indexed to 1995 96 prices were linked to the number of diagnosed HIV infected individuals using statutory medical services in England during 1996. Two cost measures were used: the first one was based on average hospital prices derived from a number of English HIV units. These results were compared with those estimated using standard unit costs obtained through specific costing studies performed at a national HIV referral centre. Overall annual expenditure on HIV service provision was estimated for different treatment scenarios as was expenditure by clinical stage of HIV infection. Using hospital prices, in 1996 the total annual cost estimate for HIV service provision amounted to 131 m range 83 m to 233 m , or 150 m 95 CI 126 m to 173 m using standard costs, if all patients with HIV disease were treated with AZT monotherapy. For all eligible patients to be treated with dual therapy, cost estimates amounted to 161 m range 126 m to 173 m per year using hospital prices or 180 m 95 CI 156 m to 203 m when using standard cost estimates, while for triple therapy annual estimated expenditure amounted to 204 m per year range 157 m to 306 m when using hospsital prices or 223 m 95 CI 199 m to 246 m using standard costs. Increasingly costs will be more evenly distributed across the 3 stages of HIV infection, with a greater proportion of costs generated by HIV infected individuals before the onset of AIDS. Using non standardized hospital prices may systematically underestimate the real cost of service provision. Monitoring prospectively the use, cost and outcome of HIV service provision in a standardized format will provide information on the actual cost impact over the next 2-3 years of combination therapy compared with the scenario based estimates produced in this paper.